Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Hong Kong Stock Exchange  >  WuXi Biologics (Cayman) Inc.    2269   KYG970081090

WUXI BIOLOGICS (CAYMAN) INC.

(2269)
  Report
End-of-day quote. End-of-day quote Hong Kong Stock Exchange - 07/31
159.6 HKD   -0.25%
07/28WUXI BIOLOGICS CAYMAN : Positive profit alert
PU
07/28WUXI BIOLOGICS CAYMAN : Date of board meeting
PU
07/24Tigermed to raise at least $1 bln in Hong Kong deal - sources
RE
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
07/27/2020 07/28/2020 07/29/2020 07/30/2020 07/31/2020 Date
143.7 150 156 160 159.6 Last
3592985 4505602 7295721 5233697 2747533 Volume
-1.03% +4.38% +4.00% +2.56% -0.25% Change
Financials
Sales 2020 5 243 M 752 M 752 M
Net income 2020 1 306 M 187 M 187 M
Net cash position 2020 4 245 M 609 M 609 M
P/E ratio 2020 149x
Yield 2020 -
Sales 2021 7 380 M 1 058 M 1 058 M
Net income 2021 1 891 M 271 M 271 M
Net cash position 2021 4 310 M 618 M 618 M
P/E ratio 2021 102x
Yield 2021 -
Capitalization 195 B 27 951 M 27 948 M
EV / Sales 2020 36,4x
EV / Sales 2021 25,8x
Nbr of Employees 5 666
Free-Float 74,0%
More Financials
Company
WUXI BIOLOGICS (CAYMAN) INC. is an investment holding company. The Company along with its subsidiaries is mainly engaged in the discovery, research and development, manufacturing and sales of biologics products. The Company’s primary products include the clinical active pharmaceutical ingredients, sterile liquid preparations, freeze-dried preparations, as well as small molecules antibiotics for injection drugs.... 
Sector
Pharmaceuticals
Calendar
08/24Earnings Release
More about the company
Surperformance© ratings of WuXi Biologics (Cayman) In
Trading Rating : Investor Rating :
More Ratings
Latest news on WUXI BIOLOGICS (CAYMAN) IN
07/28WUXI BIOLOGICS CAYMAN : Positive profit alert
PU
07/28WUXI BIOLOGICS CAYMAN : Date of board meeting
PU
07/24Tigermed to raise at least $1 bln in Hong Kong deal - sources
RE
07/24Tigermed to raise at least $1 billion in Hong Kong deal
RE
07/24Tigermed to raise at least $1 bln in Hong Kong deal - sources
RE
06/29WUXI BIOLOGICS CAYMAN : to Raise US$784.9 Million via Share Placement
DJ
05/20Wuxi Biologics's Controlling Shareholders to Raise HK$7.63 Billion via Block ..
DJ
02/18Wuxi Biologics JV Signs Vaccine Manufacturing Contract Worth Up to $3 Billion
DJ
02/18WUXI BIOLOGICS CAYMAN : Voluntary announcement vaccine manufacturing agreement f..
PU
01/09WUXI BIOLOGICS : Controlling Shareholder to Sell 4.69% Stake via Block Trade
DJ
01/09WUXI BIOLOGICS : and Almirall Sign Strategic Collaboration Agreement for Multipl..
PR
2019WUXI BIOLOGICS CAYMAN : Grant of restricted shares under restricted share award ..
PU
2019WUXI BIOLOGICS CAYMAN : Next Day Disclosure Return
PU
2019WUXI BIOLOGICS CAYMAN : (1) placing of new shares under general mandate on fully..
PU
2018WUXI BIOLOGICS : Announced Exclusive Discovery Research with Brii Biosciences fo..
PR
More news
News in other languages on WUXI BIOLOGICS (CAYMAN) IN
07/28WUXI BIOLOGICS CAYMAN : Positive profit alert
07/28WUXI BIOLOGICS CAYMAN : Date of board meeting
07/24Tigermed to raise at least $1 bln in Hong Kong deal - sources
07/24Tigermed to raise at least $1 billion in Hong Kong deal
07/24Tigermed to raise at least $1 bln in Hong Kong deal - sources
More news
Chart WUXI BIOLOGICS (CAYMAN) INC.
Duration : Period :
WuXi Biologics (Cayman) Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends WUXI BIOLOGICS (CAYMAN) IN
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Average target price 135,13 CNY
Last Close Price 143,62 CNY
Spread / Highest target 50,5%
Spread / Average Target -5,92%
Spread / Lowest Target -31,0%
EPS Revisions
Managers
NameTitle
Zhi Sheng Chen Chief Executive Officer & Executive Director
Ge Li Non-Executive Chairman
Shao Hua Lu-Wong Chief Financial Officer
Weichang Zhou Executive Director, Chief Technology Officer & EVP
Edward Hu Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
WUXI BIOLOGICS (CAYMAN) INC.61.78%27 951
CSL LIMITED-2.05%87 881
BIOGEN INC.-7.43%43 487
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.274.55%42 666
SAMSUNG BIOLOGICS CO.,LTD.69.28%40 657
UCB53.53%24 353